The US Food and Drug Administration has issued warnings to 3 companies selling kratom-containing products with unsubstantiated claims regarding their effectiveness in conditions that include opioid withdrawal and addiction and chronic pain.
The recall is due to samples of the product testing positive for Salmonella.
According to the authors, this is the first report of kratom-induced hyperprolactinemia.
The FDA said it wants all companies making kratom products to take them off the market, and urged all consumers who have kratom-containing products to stop using them and throw them away.
An investigation of the 25 most prevalent compounds in kratom showed that these compounds share structural similarities with controlled opioid analgesics, such as morphine derivatives.
The Food and Drug Administration's Commissioner Scott Gottlieb, MD, has issued a statement regarding the deadly risks associated with the botanical substance, kratom.
The DEA's plan to list kratom as a Schedule I controlled substance would make researching the possible opioid substitute much more difficult.
Clinical Pain Advisor Articles
- FDA Takes Steps to Reconcile Needs of Patients With Chronic Pain, Efforts to Curb Opioid Epidemic
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Stat Consult: Chronic Low Back Pain
- Opioid Misuse May Help Predict Alcohol Dependence Treatment Outcomes
- Neuropathic Symptoms Worsen Quality of Life, Function in Hip, Knee Osteoarthritis
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Switching From Buprenorphine-Naltrexone to XR-Naltrexone as Effective as XR-Naltrexone
- Treatment for Opioid Use Disorder Associated With Reduced Risk for Opioid-Related Deaths
- History of Migraine May Be Associated With Higher Risk for Cochlear Disorders
- Symptom Severity, Sensory Sensitivity May Indicate Pain Centralization in Chronic Overlapping Pain Conditions
- Human Diagnosis Project Aims to Address Challenges Among Uninsured
- Healthcare Technology Affects Younger Patient Satisfaction
- FDA Announces New Drug Shortages Task Force